Current Report Filing (8-k)
June 24 2022 - 5:11PM
Edgar (US Regulatory)
0001335105
false
0001335105
2022-06-24
2022-06-24
0001335105
LIXT:CommonStockParValue0.0001Member
2022-06-24
2022-06-24
0001335105
LIXT:WarrantsToPurchaseCommonMember
2022-06-24
2022-06-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 24, 2022
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
delaware |
|
001-39717 |
|
20-2903526 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
680
East Colorado Boulevard, Suite 180
Pasadena,
California 91101
(Address
of principal executive offices)
(631)
830-7092
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (See General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value $0.0001
per share |
|
LIXT |
|
The
Nasdaq Stock Market LLC |
Warrants to purchase Common
Stock, par value $0.0001 per share |
|
LIXTW |
|
The
Nasdaq Stock Market LLC |
Item
3.01 Notice of Delisting or Failure to Satisfy a Continue Listing Rule or Standard; Transfer of Listing
On
June 24, 2022, Lixte Biotechnology Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NASDAQ Stock Market LLC (“Nasdaq”) that the Company has not been in compliance with the minimum bid price requirement
set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed
securities to maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure
to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The
Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market.
In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days from the date of
the Notice, or until December 21, 2022, to regain compliance with the minimum closing bid price requirement. If the Company does not
regain compliance during the compliance period ending December 21, 2022, the Company may be afforded a second 180 calendar day period
to regain compliance. To qualify for the second compliance period, the Company must (i) meet the continued listing requirement for market
value of publicly-held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum
closing bid price requirement, and (ii) notify Nasdaq of its intent to cure the deficiency. The Company can achieve compliance with the
minimum closing bid price requirement if, during either compliance period, the minimum closing bid price per share of the Company’s
common stock is at least $1.00 for a minimum of 10 consecutive business days. The Company anticipates that its shares of common stock
will continue to be listed and traded on the Nasdaq Capital Market during the compliance period(s).
The
Company plans to carefully assess potential actions to regain compliance. However, the Company may be unable to regain compliance with
the minimum closing bid price requirement during the compliance period(s), in which case the Company anticipates Nasdaq would provide
a notice to the Company that its shares of common stock are subject to delisting, and the Company’s common shares would thereupon
be delisted.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
June 24, 2022 |
LIXTE
BIOTECHNOLOGY HOLDINGS, INC. |
|
|
|
|
By: |
/s/
JOHN S. KOVACH |
|
|
John
S. Kovach, Chief Executive Officer |
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2024 to May 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From May 2023 to May 2024